Rockefeller Capital Management L.P. Grows Position in IDEXX Laboratories, Inc. $IDXX

Rockefeller Capital Management L.P. grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,826 shares of the company’s stock after purchasing an additional 3,400 shares during the period. Rockefeller Capital Management L.P. owned approximately 0.07% of IDEXX Laboratories worth $29,406,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of IDXX. STF Management LP lifted its position in IDEXX Laboratories by 1.3% during the second quarter. STF Management LP now owns 1,240 shares of the company’s stock valued at $665,000 after buying an additional 16 shares in the last quarter. Clearstead Trust LLC raised its stake in shares of IDEXX Laboratories by 1.1% in the 2nd quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock valued at $813,000 after acquiring an additional 16 shares during the period. Stratos Wealth Partners LTD. lifted its holdings in shares of IDEXX Laboratories by 1.7% during the 2nd quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock valued at $564,000 after acquiring an additional 18 shares in the last quarter. Red Spruce Capital LLC boosted its position in IDEXX Laboratories by 1.1% during the 2nd quarter. Red Spruce Capital LLC now owns 1,701 shares of the company’s stock worth $912,000 after purchasing an additional 19 shares during the period. Finally, Huntington National Bank boosted its position in IDEXX Laboratories by 0.5% during the 2nd quarter. Huntington National Bank now owns 3,651 shares of the company’s stock worth $1,958,000 after purchasing an additional 19 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Stifel Nicolaus set a $775.00 price objective on IDEXX Laboratories in a research note on Monday, November 3rd. JPMorgan Chase & Co. boosted their price target on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. UBS Group upped their price target on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. Morgan Stanley lifted their price objective on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Finally, Leerink Partners set a $785.00 target price on shares of IDEXX Laboratories in a research note on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $730.50.

IDEXX Laboratories Stock Down 3.0%

IDXX stock opened at $669.00 on Tuesday. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The firm has a 50 day simple moving average of $652.07 and a 200-day simple moving average of $591.26. The company has a market capitalization of $53.42 billion, a P/E ratio of 55.70, a PEG ratio of 4.06 and a beta of 1.62. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $735.00.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, November 3rd. The company reported $3.22 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. The firm had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The firm’s revenue was up 13.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the transaction, the executive vice president directly owned 21,149 shares in the company, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director M Anne Szostak sold 2,187 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total value of $1,415,710.71. Following the sale, the director owned 262 shares in the company, valued at $169,600.46. The trade was a 89.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.98% of the stock is currently owned by company insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.